Minerva Surgical (Minerva Surgical) Growth Rank : 0 (As of May. 23, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Minerva Surgical Growth Rank?

Minerva Surgical has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Minerva Surgical Growth Rank Related Terms

Thank you for viewing the detailed overview of Minerva Surgical's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Minerva Surgical (Minerva Surgical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Minerva Surgical Inc (OTCPK:UTRS) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

4255 Burton Drive, Santa Clara, CA, USA, 95054

Website

https://www.minervasurgical.com

Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.

Executives

Daniel Cohen	director	C/O ACCELMED, 848 BRICKELL AVE, #901, MIAMI FL 33131
Accelmed Partners Ii L.p.	10 percent owner	2875 NE 191ST, SUITE 500, AVENTURA FL 33180
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Uri Geiger	director, 10 percent owner	221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Todd Usen	director, officer: Chief Executive Officer	C/O MINERVA SURGICAL, INC., 4255 BURTON DRIVE, SANTA CLARA CA 95054
Derrick Sung	director	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
David M Clapper	director, officer: President and CEO	3003 TASMAN DRIVE, SANTA CLARA CA 95054
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jaffe Ross A Md	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Evgueni V. Skalnyi	officer: VP Medical Affairs	C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Dominique J. Filloux	officer: COO	C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Joel R Jung	officer: CFO	1401 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Niquette L. Hunt	director	SOLITON, INC., 5304 ASHBROOK DRIVE, HOUSTON TX 77081
Jill Anderson	director	1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202